WuXi fall­out re­ver­ber­ates; Phar­ma's top R&D spenders; Lil­ly teams up with Ama­zon; His­toric NASH ap­proval; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Boast­ing alert: We learned just a few days ago that End­points News won a gen­er­al ex­cel­lence award from the So­ci­ety for Ad­vanc­ing Busi­ness Edit­ing and Writ­ing. It’s a de­light­ful recog­ni­tion of the team’s hard work. A big thank you to the sub­scribers and part­ners who sup­port us — we couldn’t do it with­out you.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER